



ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gen G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Milionig
Lawrence B. Bugaiksy
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Teresa U. Medier
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes

Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhuillier
Rae Lynn P. Guest
George S. Bardmessier
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford*
Helene C. Carlson
Timothy A. Doyle*
Gaby L. Longsworth
Lori A. Gordon*

Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer*
Laura A. Vogel
Michael J. Mancuso
Registered Patent Agents
Karen R. Markowitz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katrina Yulian Pei Quach
Bryan L. Sketton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek

Robert H. DeSelms
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Michael G. Penn
Christopher J. Walsh

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
+Admitted only in Virginia
•Practice Limited to
Federal Agencies

December 10, 2004

WRITER'S DIRECT NUMBER:

(202) 772-8525

INTERNET ADDRESS:

BRIAND@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1641

Re: U.S. Utility Patent Application
Application No. 10/743,295; Filed: December 23, 2003
For: **Polymer Conjugates of Cytokines, Chemokines, Growth Factors, Polypeptide Hormones and Antagonists Thereof with Preserved Receptor-Binding Activity**
Inventors: BHASKARAN *et al.*
Our Ref: 2057.0060002/JAG/BJD

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Second Supplemental Information Disclosure Statement;
2. A listing of the cited documents on Form PTO-1449;
3. A copy of the cited document (AS40);
4. Corrected Form PTO-1449, page 1 of 36 and page 3 of 36; and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 10, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

BJD/SAC/jk
Enclosures

343545



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bhaskaran *et al.*

Appl. No.: 10/743,295

Filed: December 23, 2003

For: **Polymer Conjugates of Cytokines,
Chemokines, Growth Factors,
Polypeptide Hormones and
Antagonists Thereof with Preserved
Receptor-Binding Activity**

Confirmation No.: 7998

Art Unit: 1641

Examiner: *To be assigned*

Atty. Docket: 2057.0060002/JAG/BJD

Second Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed September 28, 2004, in connection with the above-captioned application.

Copies of documents AA9-AF9 are not provided in accordance with the Changes To Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan, effective October 21, 2004, which states "section 1.98(a)(2)(i) is amended to eliminate the requirement in paragraph (a)(2)(i) for a copy of each U.S. patent or U.S. patent application publication listed in an IDS in a patent application regardless of the filing date of the application." A copy of each other document is provided.

Applicants would like to bring to the Examiner's attention that an inadvertent error was made without deceptive intent in the listing of two of the patent numbers in the original Information

Disclosure Statement filed on September 28, 2004. Document **AE1** should be U.S. Patent No. 4,462,940, not 4,462,946. Document **AD3** should be U.S. Patent No. 5,446,090, not 5,449,090. Applicants apologize for any inconvenience caused to the Office, and respectfully request that the Corrected Form PTO-1449 pages submitted herewith be substituted for the original Form PTO-1449 pages submitted with the Information Disclosure Statement.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

Bhaskaran *et al.*
Appl. No. 10/743,295

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: Dec. 10, 2004
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
333544_1.DOC



FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2057.0060002/JAG/BJD	APPLICATION NO. 10/743,295
	APPLICANT BHASKARAN et al.	
	FILING DATE December 23, 2003	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA9	4,588,585	05/13/1986	Mark et al.	424	85	09/28/1984
	AB9	5,460,811	10/24/1995	Goeddel et al.	424	85.6	06/12/1989
	AC9	6,482,613 B1	11/19/2002	Goeddel et al.	435	69.51	01/19/1988
	AD9	2002/0172661 A1	11/21/2002	Shirley et al.	424	85.6	10/25/2001
	AE9	2004/0181035 A1	09/16/2004	Kinstler et al.	530	350	03/26/2001
	AF9	2004/0191219 A1	09/30/2004	Shirley et al.	424	85.6	04/09/2004
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM5						Yes No
	AN5						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR				
AS	40		Unverified partial translation of Doc. No. AP4 (WO 04/046222 A1), pages 12-13 (Tables 1 and 2); and 79-92 (Example 35, and claims 1-29).	
AT	40			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

CORRECTED FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2057.0060002/JAG/BJD		APPLICATION NO. 10/743,295
	APPLICANT BHASKARAN et al.		
	FILING DATE December 23, 2003		GROUP 1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	5,362,852	11/08/1994	Geoghegan et al.			09/27/1991
	AB3	5,382,657	01/17/1995	Karasiewicz et al.			08/26/1992
	AC3	5,395,619	03/07/1995	Zalipsky et al.			03/03/1993
	AD3	5,446,090	08/29/1995	Harris			11/12/1993
	AE3	5,468,478	11/21/1995	Saifer et al.			10/18/1993
	AF3	5,476,653	12/19/1995	Pitt et al.			03/22/1995
	AG3	5,539,063	07/23/1996	Hakimi et al.			06/01/1995
	AH3	5,605,976	02/25/1997	Martinez et al.			05/15/1995
	AI3	5,612,460	03/18/1997	Zalipsky			02/17/1994
	AJ3	5,643,575	07/01/1997	Martinez et al.			10/27/1993
	AK3	5,672,662	09/30/1997	Harris et al.			10/02/1995

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	WO 99/55377 A2	11/04/1999	WIPO			Yes No
	AM3	WO 99/58142 A1	11/18/1999	WIPO			Yes No
	AN3	WO 00/07629 A2 and A3	02/17/2000	WIPO			Yes No
	AO3	WO 00/23114 A2 and A3	04/27/2000	WIPO			Yes No
	AP3	WO 01/02017 A2 and A3	01/11/2001	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	3	Bamborough, P., et al., "The interleukin-2 and interleukin-4 receptors studied by molecular modeling," <i>Structure</i> 2:839-851, Elsevier Science Ltd. (1994)
AS	3	Basser, R.L., et al., "Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor," <i>Blood</i> 99:2599-2602, The American Society of Hematology (April 2002)
AT	3	Bertolotto, A., et. al., "Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory," <i>J. Neurol. Neurosurg. Psychiatry</i> . 73:148-153, BMJ Publishing Group (April 2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



DEC 10 2004

CORRECTED FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
2057.0060002/JAG/BJDAPPLICATION NO.
10/743,295APPLICANT
BHASKARAN et al.FILING DATE
December 23, 2003GROUP
1641

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	4,002,531	01/11/1977	Royer			01/22/1976
	AB1	4,179,337	12/18/1979	Davis et al.			07/28/1977
	AC1	4,261,973	04/14/1981	Lee et al.			08/08/1977
	AD1	4,301,144	11/17/1981	Iwashita et al.			07/10/1980
	AE1	4,462,940	07/31/1984	Hanisch et al.			05/18/1983
	AF1	4,609,546	09/02/1986	Hiratani			06/23/1983
	AG1	4,732,863	003/22/1988	Tomasi et al.			12/31/1984
	AH1	4,816,440	03/28/1989	Thomson			09/26/1985
	AI1	4,894,330	01/16/1990	Hershenson et al.			12/23/1986
	AJ1	4,902,502	02/20/1990	Nitecki et al.			01/23/1989
	AK1	4,904,584	02/27/1990	Shaw			12/23/1987

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	EP 0 098 110 B1	10/18/1989	Europe			Yes No
	AM1	EP 0 733 067 B1	05/12/1999	Europe			Yes No
	AN1	EP 1 039 922 B1	06/12/2002	Europe			Yes No
	AO1	EP 0 822 199 A2 and A3	02/04/1998	Europe			Yes No
	AP1	WO 89/01033 A1	02/09/1989	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>1</u>	Abuchowski, A., et al., "Immunosuppressive properties and circulating life of <i>Achromobacter glutaminase-asparaginase</i> covalently attached to polyethylene glycol in man," <i>Cancer Treat Rep</i> 65:1077-1081, Kluwer Academic (1981)
AS	<u>1</u>	Abuchowski, A., et al., "Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates," <i>Cancer Biochem Biophys</i> 7:175-186, Gordon & Breach (1984)
AT	<u>1</u>	Abuchowski, A., et al., "Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase," <i>J Biol Chem</i> 252:3582-3586, The American Society for Biochemistry and Molecular Biology (1977)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.